Site icon Impactiviti

Impactiviti Daily 100609

Now Available – My archived interview on Social Media in Pharma with Paul Chaney – feel free to forward the link (http://bit.ly/29kAoN) to your colleagues.

TODAY’S NEWS

BMS/Astra diabetes drug cleared in Europe ONGLYZA is indicated as a once-daily 5 mg oral tablet dose in adult patients with type 2 diabetes mellitus to improve glycaemic controlmore

FDA panel gives thumbs up to new GSK cancer drug –  A Food and Drug Administration panel Monday unanimously backed a proposed GlaxoSmithKline PLC drug for treating kidney cancer, despite agency concerns about a risk of severe liver injury. Glaxo is seeking FDA approval of the drug, pazopanib, to treat patients with advanced kidney cancer. The product was reviewed by outside medical experts who serve on the agency’s oncologic drugs advisory committeemore

Novartis CEO Vasella comes out swinging against animal rights terrorists. Good for him.

Physician smartphone usage – on the rise!

RECOMMENDED

Virtual Worlds and other on-line platforms for training or meetings. Impactiviti’s suite of partners can help you design and roll-out these advanced applications. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) to talk.

PLUS

Eighteen minutes that will rattle your world and challenge your assumptions about motivation in business. Dan Pink at TED – a great presenter, and very thought-provoking.

JUST FOR FUN

Dilbert on management evaluation.

Coming up this month:

Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Exit mobile version